文献速递头颈外科鼻科耳科与耳神经

颅面骨尤文肉瘤:一项定性系统综述

Ewing Sarcoma of the Craniofacial Bones: A Qualitative Systematic Review.
PubMed 文献 · Otolaryngol Head Neck Surg · 2021-07-13

该系统综述纳入71项研究共102例颅面骨尤文肉瘤患者,最常见的部位为额骨、鼻腔和颞骨,最常用治疗为手术联合放疗和化疗,多数患者(79.0%)无复发,预后良好,但受回顾性数据限制。

要点

  • 颅面骨尤文肉瘤常见于额骨、鼻腔和颞骨。
  • 手术联合放疗和化疗是最常用方案,局部复发率16.6%。
  • 多数患者(79.0%)治疗后无病生存,预后较好。

核心结论

  • 颅面骨尤文肉瘤经适当治疗预后良好。

研究设计与样本

  • 系统综述通过Cochrane Library、EmBase和PubMed数据库检索,纳入71项研究共102例患者。

主要发现

  • 最常见部位为额骨(16.7%,n=17)、鼻腔(16.7%,n=17)和颞骨(14.7%,n=15)。
  • 额骨最常见症状为可触及肿块(n=8,47.1%),鼻腔为鼻出血(n=9,52.9%),颞骨为头痛(n=5,33.3%)。
  • 最常用治疗为手术联合放疗和化疗(n=43,43%),其次为放疗联合化疗(n=18,18%)和手术联合化疗(n=15,15%)。
  • 接受手术联合放疗和化疗的患者局部复发率为16.6%,其他联合方案复发率更低但样本量小。
  • 79.0%的患者无病生存且无复发证据。

临床怎么用

  • 临床医生应结合本文发现与自身临床判断决定治疗策略。

局限性

  • 研究受限于回顾性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To conduct a systematic review on the demographics, characteristics, management, treatment, complications, and outcomes of Ewing sarcomas in the craniofacial bones. DATA SOURCES: Using Cochrane Library, EmBase, and PubMed, the authors identified 71 studies to be included. REVIEW METHODS: The Cochrane Library, EmBase, and PubMed databases were used to identify literature relating to Ewing sarcomas in the craniofacial bone to conduct a systematic review. Patient demographics, clinical characteristics, and treatment strategies were extracted. RESULTS: Seventy-one studies encompassing 102 patients were identified. The most common craniofacial locations involved were the frontal bone (16.7%, n = 17), nasal cavity (16.7%, n = 17), and temporal bone (14.7%, n = 15). Stratified by location, the most common presenting symptoms were frontal bone (palpable mass, n = 8, 47.1%), nasal cavities (epistaxis, n = 9, 52.9%), and temporal bones (headache, n = 5, 33.3%). The 3 most commonly used treatment strategies were a combination of surgical intervention/radiotherapy/chemotherapy (n = 43, 43%), a combination of radiotherapy/chemotherapy (n = 18, 18%), and a combination of surgical intervention/chemotherapy (n = 15, 15%). Patients who received a combination of surgical intervention/radiotherapy/chemotherapy experienced local recurrence rate of 16.6%. However, other combinations of therapies such as surgical intervention/chemotherapy and radiotherapy/chemotherapy had a lower local recurrence rate but were limited by small sample size. Most patients (79.0%) were disease free without evidence of recurrence. CONCLUSION: Ewing Sarcoma of the craniofacial bones has a good prognosis when treated appropriately. Given that our study was limited by retrospective data, we advise clinicians to use the findings of this article with their own clinical judgment to determine which treatment strategy they should pursue.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Rehman R, Osto M, Parry N, et al. Ewing Sarcoma of the Craniofacial Bones: A Qualitative Systematic Review. Otolaryngol Head Neck Surg. 2021. PMID: 34255595. doi:10.1177/01945998211022228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。